536-25-4

Basic information

• Product Name: Methyl 3-amino-4-hydroxybenzoate
• Synonyms: ORTHOFORM;ORTHOCAINE;3-Amino-4-hydroxybenzoic acid methyl ester;3-amino-4-hydroxy-benzoicacimethylester;Aminobenz;Methyl 4-hydroxy-3-aminobenzoate;Methyl m-amino-p-hydroxybenzoate;Orthoderm
• CAS NO: 536-25-4
• Molecular Formula: C₈H₉NO₃
• Molecular Weight: 167.16
• EINECS: 208-627-3
• Product Categories: Aromatic Esters;Acids & Esters;Anilines, Amides & Amines;Phenols;Esters;Phenyls & Phenyl-Het;Amines;Aromatics;Intermediates;Miscellaneous Reagents
• Mol File: 536-25-4.mol
• Article Data: 42

Chemical Properties

• Melting Point: 141-143
• Boiling Point: 295.73°C (rough estimate)
• Flash Point: 151.444 °C
• Appearance: /Solid
• Density: 1.2917 (rough estimate)
• Vapor Pressure: 0.000111mmHg at 25°C
• Refractive Index: 1.5810 (estimate)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 8.15±0.18(Predicted)
• CAS DataBase Reference: Methyl 3-amino-4-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-amino-4-hydroxybenzoate(536-25-4)
• EPA Substance Registry System: Methyl 3-amino-4-hydroxybenzoate(536-25-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• RTECS: DG2625000
• TSCA: Yes
• HazardClass: IRRITANT
• Hazardous Substances Data: 536-25-4(Hazardous Substances Data)

Usage

Chemical Properties

Beige Solid

Uses

Anesthetic (topical).

InChI:InChI=1/C8H9NO3/c1-12-8(11)5-2-3-7(10)6(9)4-5/h2-4,10H,9H2,1H3

Upstream product

• 99-42-3 methyl (4-hydroxy-3-nitro)benzoate 
• 67-56-1 methanol 
• 1571-72-8 3-amino-4-hydroxybenzoic acid 
• 91-66-7 N,N-diethylaniline 
• 616-82-0 3-nitro-4-hydroxybenzoic acid 
• 75-36-5 acetyl chloride 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 82525-66-4 3-(2-chloro-acetylamino)-4-hydroxy-benzoic acid methyl ester 
• 82525-67-5 4-hydroxy-3-{[N-(2-hydroxy-5-methoxycarbonyl-phenyl)-glycyl]-amino}-benzoic acid methyl ester 
• 72730-39-3 methyl 2-thioxo-2,3-dihydrobenzo[d]oxazole-5-carboxylate 
• 65422-70-0 methyl 2-oxo-2,3-dihydro-1,3-benzoxazole-5-carboxylate 
• 6332-66-7 3-(2-carbamoylsulfanyl-acetylamino)-4-hydroxy-benzoic acid methyl ester 
• 5852-78-8 8-hydroxy-quinoline-5-carboxylic acid 
• 220844-97-3 methyl 4-hydroxy-3-methylaminobenzoate 
• 316158-20-0 methyl 3-(dimethylamino)-4-hydroxybenzoate 
• 1571-72-8 3-amino-4-hydroxybenzoic acid 
• 220844-96-2 methyl 4-hydroxy-3-ethylaminobenzoate 
• 934593-90-5 3-[2-(4-adamantan-1-yl-phenoxy)-acetylamino]-4-hydroxy-benzoic acid methyl ester 
• 604756-32-3 methyl 3-oxo-3,4-dihydro-2H-1,4-benzoxazine-6-carboxylate 
• 924869-17-0 benzoxazole-5-carboxylic acid methyl ester 
• 136663-21-3 methyl 2-methyl-1,3-benzoxazole-5-carboxylate 

Relevant articles and documents

Synthesis and biological activities of some Novel 2-Amino-(5 or 7-Substituted- 2-Oxoindolin-3-Ylidene) Benzoxazole-5-Carbohydrazide derivatives

A series of 2-amino-(5 or 7-substituted-2-oxoindolin-3-ylidene) benzoxazole-5-carbohydrazide derivatives were synthesized by treating 2-aminobenzoxazole-5-carbohydrazide with different substituted isatins. All the synthesized derivatives (VI a-l) were screened for their in vitro anticancer (against HeLa, IMR-32 & MCF-7 cancer cell lines), antioxidant (against DPPH radicals) and antimicrobial activities. The results of these studies showed the dose dependant anticancer, antioxidant and antimicrobial activities of the test compounds and the IC50 values of some compounds were comparable with their standard agent. The test compounds having substitution with different electron withdrawing groups at C-5 position showed more potent anticancer, antioxidant and antibacterial activities than those at C-7 position.

Heterocyclic substituted biphenyl compound as well as preparation method and application thereof

The invention discloses a heterocyclic substituted biphenyl compound as well as a preparation method and application thereof. According to the present invention, the compound can block the PD-1/PD-L1 signal pathway, and can be used as the immune checkpoint PD-1/PD-L1 small molecule inhibitor; and according to the compound disclosed by the invention, the metabolic stability is improved while the high binding rate with PD-L1 protein is maintained. A hydrophilic group is introduced to a heterocyclic ring, and the PD-1/PD-L1 inhibitory activity is improved.

Synthesis, Structure Revision, and Cytotoxicity of Nocarbenzoxazole G

The total synthesis of nocarbenzoxazoles F (1) and G (2), originally obtained from the marine-derived halophilic bacterial strain Nocardiopsis lucentensis DSM 44048, was achieved via a simple and versatile route involving microwave-assisted construction of a benzoxazole skeleton, followed by carbon-carbon bond formation with the corresponding aryl bromides. Unfortunately, the 1H and 13C NMR spectra of natural nocarbenzoxazole G did not agree with those of the synthesized compound. In particular, the spectra of the isolated and synthesized compounds showed considerable differences in the signals from the protons and carbons in the aryl group. The revised structure was validated by the total synthesis of the actual nocarbenzoxazole G (8c) molecule, which is a regioisomer of the compound that was reported earlier as nocarbenzoxazole G. The synthesized derivatives showed specific cytotoxicity to the human cervical carcinoma cell line, HeLa, but did not have any remarkable effect on the other cell lines.